The FDA has approved Eli Lilly’s new migraine drug lasmiditan, offering patients a new option to relieve symptoms should they feel an attack coming on.
Alder BioPharmaceuticals has filed its migraine drug eptinezumab with the US regulator, the last in a gang of four CGRP-class antibodies developed to treat the condition.
Researchers at the University of Florida have developed a new mRNA-based vaccine that, when combined with checkpoint inhibitor immunotherapy, significantly boosted anti-tumour activit